arrow
Z

Zhanhong Xie

Guangzhou Medical University
H指数:23
被引数:1,923

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

International Consensus on Severe Lung Cancer-The Second Edition

国际重症肺癌共识(第二版)

2026-04-300
PRE
First-line camrelizumab plus pemetrexed and carboplatin for advanced non-squamous non-small-cell lung cancer with brain metastases (CAP-BRAIN): final results of a multicentre, open-label, single-arm, phase 2 trial in China

一线卡瑞利珠单抗联合培美曲塞和卡铂治疗伴脑转移的晚期非鳞非小细胞肺癌(CAP-BRAIN):一项在中国进行的多中心、开放标签、单臂、II期试验的最终结果

2025-11-120
OAAI
Sintilimab plus chemotherapy for first-line treatment of advanced pulmonary lymphoepithelioma-like carcinoma: Phase 2 trial

信迪利单抗联合化疗用于晚期肺淋巴上皮样癌的一线治疗:2期临床试验

2025-10-060
OAAI
Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial

诱导化疗后采用卡瑞利珠单抗联合阿帕替尼和化疗作为广泛期小细胞肺癌的一线治疗:一项多中心、单臂试验

2025-02-180
OA
Case report: Therapeutic response of front-line cadonilimab plus chemotherapy on patient with advanced lung adenocarcinoma harboring STK11 genetic aberration

病例报告: 一线卡多尼单抗加化疗对患有STK11遗传畸变的晚期肺腺癌患者的治疗反应

2024-12-090
OAAI
Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma
2024-08-011
OAAI
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease

肺癌合并慢性阻塞性肺疾病诊治国际专家共识

2023-08-019
OAAI
Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study
2022-11-0112
OAAI
Treatment response and safety of immunotherapy for advanced non-small cell lung cancer with comorbid chronic obstructive pulmonary disease: a retrospective cohort study

晚期非小细胞肺癌合并慢性阻塞性肺疾病患者免疫治疗的疗效和安全性的回顾性队列研究

2022-11-018
OAAI
Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis
2022-07-208
OAAI